ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting

    Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”

    Ana Urruticoechea-Arana1, Tatiana Cobo-Ibáñez2, Virginia Villaverde García3, Montserrat Santos-Gómez4, Kelly Vargas Osorio5, Federico Díaz-González6, Leslie Fariñas Padrón5, Vanesa Calvo-Río7 and Ricardo Blanco Alonso7, 1Hospital Can Misses, Ibiza, Spain, 2Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, 4Rheumatology, Hospital Can Misses, Ibiza, Spain, 5Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, 6Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, 7Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain

    Background/Purpose:
  • Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting

    Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients

    Lucia Cristina Domínguez-Casas1, Vanesa Calvo-Río1, Ricardo Blanco2, Carlos Fernández-Díaz1, Paz Rodríguez-Cundín3, Emma Beltran4, Marisa Hernández-Garfella5, Jose M Herreras6, Miguel Cordero-Coma7, Marina Mesquida8, Alfredo Adan9, M. Victoria Hernández10, David Diaz-Valle11, Ignacio Torre-Salaberri12, Manuel Díaz-Llopis13, Roberto Gallego14, Olga Maiz-Alonso15, Santos Insua16, Félix Francisco17, Raquel Almodóvar González18, Oscar Ruiz Moreno19, Fernando Jiménez-Zorzo20, Javier Manero21, Myriam Gandía22, Joan Miquel Nolla23, Nuria Vegas-Revenga24, Natalia Palmou-Fontana1 and Miguel Angel Gonzalez-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 2Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 4Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, 5Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, 6Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, 7Ophthalmology, Hospital de León, León, Spain, 8Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 9Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, 10Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 11Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, 12Rheumatology, Hospital de Basurto, Bilbao, Spain, 13Hospital Universitario La Fe, Valencia, Spain, 14Ophtalmology, Hospital Universitario La Fe, Valencia, Spain, 15Hospital Universitario Donostia, Donostia, Spain, 16Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, 17Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, 18Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, 19Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, 20Hospital Miguel Servet, Zaragoza, Spain, 21Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 22Rheumatology, Hospital Puerta del Mar, Cadiz, Spain, 23Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 24Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain

    Background/Purpose:   Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…
  • Abstract Number: 2948 • 2016 ACR/ARHP Annual Meeting

    Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study

    Sinem Nihal Esatoglu1, Ibrahim Hatemi2, Yesim Ozguler3, Gulen Hatemi3, Hafize Uzun4, Aykut Ferhat Celik5 and Hasan Yazici3, 1Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

    Background/Purpose: The fecal calprotectin (FC) is widely used as a non-invasive method for identifying patients with active Crohn’s disease (CD) and ulcerative colitis. Gastrointestinal involvement…
  • Abstract Number: 2949 • 2016 ACR/ARHP Annual Meeting

    Surgical Method for Aortic Root Involvement of Behcet Disease

    Byeongzu Ghang1, Suk Jung Choo2, Oh Chan Kwon3, Seokchan Hong4, Yong-Gil Kim5, Chang-Keun Lee5 and Bin Yoo5, 1Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Division of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, 3Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, 4Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

    Background/Purpose:  Aortic regurgitation (AR) in Behcet disease is a rare but very fatal condition. Many patients require a second or third operation after simple aortic…
  • Abstract Number: 2959 • 2016 ACR/ARHP Annual Meeting

    Baseline Endothelial Dysfunction Might Predict Immunosuppressive Need in Young, Male Behcet’s Patients with Early Disease: A Prospective Follow-up

    Fatma Alibaz-Oner1, Emrah Karatay2, Belgin Aldag1, I.Nuri Akpınar2, Tulin Ergun3 and Haner Direskeneli4, 1Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 2Radiology, Marmara University, School of Medicine, Istanbul, Turkey, 3Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: Major organ involvement, especially in young males, is one of the main causes of mortality and morbidity in Behcet’s Disease (BD). However, the prognosis…
  • Abstract Number: 2963 • 2016 ACR/ARHP Annual Meeting

    BehçEt’s Disease in Children: Eastern Mediterranean Experience

    Hafize Emine Sonmez1, Ezgi Deniz Batu1, Betul Sozeri2, Yonatan Butbul Aviel3, Yelda Bilginer4 and Seza Ozen5, 1Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, 2Pediatric Rheumatology, Erciyes University Faculty of Medicine, Kayseri, Turkey, 3Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, 4Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, 5Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Background/Purpose: Behçet’s disease (BD) is a variable vessel vasculitis which is more common in adults. The most widely used diagnostic criteria for adult onset disease…
  • Abstract Number: 2966 • 2016 ACR/ARHP Annual Meeting

    Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?

    Ali Ugur Unal1, Hale Gulcin Yildirim2, Ceylan Cikikci2, Gulsen Ozen3, Nevsun Inanc3, Pamir Atagunduz3, Tulin Ergun4 and Haner Direskeneli5, 1Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 5Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: Behcet’s Disease (BD) is a systemic vasculitis characterized by involvement of vessels of any size and type. In the course systemic vasculitis, it is…
  • Abstract Number: 182 • 2016 ACR/ARHP Annual Meeting

    Histone Methylation in γδ T Cells As a Biomarker of Behcet’s Disease Activity

    Yoshimi Aizaki1,2, Yasuto Araki1,2, Kojiro Sato1, Kazuhiro Yokota1 and Toshihide Mimura1,2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose: Behcet’s disease (BD) is a chronic recurrent, multisystem inflammatory disorder. The phenotypic characteristics include oral aphtha, genital ulcers, uveitis and skin lesions. No specific…
  • Abstract Number: 2967 • 2016 ACR/ARHP Annual Meeting

    Identifying Core Domains for BehçEt’s Syndrome Trials: An International Physician and Patient Delphi Exercise

    Alexa Meara1, Yesim Ozguler2, Alfred Mahr3, Haner Direskeneli4, Ahmet Gul5, Yusuf Yazici6, Hasan Yazici2, Peter A. Merkel7 and Gulen Hatemi2, 1Internal Medicine/Rheumatology, The Ohio State University, Columbus, OH, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3Hospital Saint-Louis, Paris, France, 4Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 5Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 6Rheumatology, New York University Medical Center, La Jolla, CA, 7Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: An unmet need for reliable, validated, and widely accepted outcome measures for trials in BehetÕs syndrome (BS) was identified through: i) a systematic review;…
  • Abstract Number: 879 • 2016 ACR/ARHP Annual Meeting

    Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease

    Sinem Nihal Esatoglu1, Ayse Merve Celik2, Didar Ucar3, Aykut Ferhat Celik4, Serdal Ugurlu5, Gulen Hatemi5, Melike Melikoglu5, Izzet Fresko5, Vedat Hamuryudan5, Huri Ozdogan6, Sebahattin Yurdakul5, Hasan Yazici5 and Emire Seyahi5, 1Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 6Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: Case reports and series suggest that Takayasu’s arteritis (TA) can co-exist with various inflammatory disorders. Inflammatory bowel disease [(IBD; Crohn's disease (CD) or ulcerative…
  • Abstract Number: 2978 • 2016 ACR/ARHP Annual Meeting

    Psychiatric Involvement and Behcet’S Syndrome: Does Bipolar Disorder Represent a Clinical Feature of the Disease?

    Rosaria Talarico1, Elena Elefante2, Laura Palagini3, Anna d'Ascanio4, Chiara Stagnaro4, Chiara Tani4, Chiara Baldini4, Rossella Neri1 and Marta Mosca4, 1Rheumatology Unit, University of Pisa, PISA, Italy, 2RHEUMATOLOGY UNIT, University of Pisa, Pisa, Italy, 3Psychiatric Unit, University, PISA, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Italy

    Background/Purpose: Frequency of psychiatric disorders in Behçet’s syndrome (BS) is a debated issue: while some experts attribute their presence to the chronicity of the illness,…
  • Abstract Number: 1202 • 2016 ACR/ARHP Annual Meeting

    Characteristic Compositional and Functional Alteration of Gut Microbiota in Patients with Behcet’s Disease

    Noboru Suzuki1, Jun Shimizu2 and Takao Kubota3, 1Department of Immunology and medicine, St. Marianna University School of Medicine, Kawasaki-shi, 216-8511, Japan, 2Department of Immunology and Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 3The Japan Self Defense Forces Central Hospital, Tokyo, Japan

    Background/Purpose:  We have presented evidence that the frequency of helper T (Th)17 cells increased and the cells had already been activated in vivo in patients…
  • Abstract Number: 2979 • 2016 ACR/ARHP Annual Meeting

    a Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of BehçEt’s Syndrome Informing the Eular Recommendations for the Management of BehçEt’s Syndrome

    Pietro Leccese1, Yesim Ozguler2, Robin Christensen3, Sinem Nihal Esatoglu4, Dongsik Bang5, Bahram Bodaghi6, Aykut Ferhat Celik7, Farida Fortune8, Julien Gaudric9, Ahmet Gul10, Ina Kotter11, Alfred Mahr12, Robert J Moots13, Ignazio Olivieri14, Jutta Richter15, David Saadoun16, Carlo Salvarani17, Frances Scuderi18, PETROS P SFIKAKIS19, Aksel Siva20, Miles Stanford21, Ilknur Tugal-tutkun22, Richard West23, Sebahattin Yurdakul2, Hasan Yazici2 and Gulen Hatemi2, 1Rheumatology, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Matera, Italy, Matera, Italy, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 3The Parker instutute, RC, Copenhagen, Denmark, 4Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 5Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, Seoul, Korea, The Democratic People's Republic of, 6Ophthalmology, Pierre and Marie Curie University - Paris 6 Paris, France, Paris, France, 7Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, 8Dental Institute, Barts and The London NHS Trust, London, United Kingdom, 9Department of Vascular surgery GHPS, Paris, France, 10Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 11Internal Medicine, Robert-Bosch-Hospital, Stuttgart, Germany, 12Hospital Saint-Louis, Paris, France, 13Academic Rheumatology Unit, University of Liverpool, Liverpool, United Kingdom, 14U.O. Reumatologia, A.O. Ospedale San Carlo, Potenza, Italy, 15Tubingen University, Tubingen, Germany, 16Department of Internal Medicine and Clinical Immunology, AP-HP Pitié-Salpêtrière Hospital, Paris, France, 17Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 18Patient partner, Catania, Italy, 19First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 20Department of Neurology, Istanbul University, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey, 21Ophthalmology, Guy's and St. Thomas' Hospital, London, United Kingdom, 22Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 23Patient partner, London, United Kingdom

    A Systematic Literature Review on the Treatment of Skin, Mucosa and Joint Involvement of Behçet’s Syndrome Informing the Eular Recommendations for the Management of Behçet’s…
  • Abstract Number: 1285 • 2016 ACR/ARHP Annual Meeting

    PET/CT Imaging in Patients with Vascular Behcet Disease

    Bahtiyar Toz1, Burak Erer1, Sevil Kamali1, Murat Inanc2, Lale Ocal3 and Ahmet Gul1, 1Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey, 3Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

    Background/Purpose: BehetÕs disease (BD) is a multisystemic disease characterized by recurrent inflammatory manifestations. BD is classified as variable vessel vasculitis. While inflammatory thrombotic venous findings…
  • Abstract Number: 3043 • 2016 ACR/ARHP Annual Meeting

    Dense Genotyping of Immune Related Loci in a Multi-Ethnic Behçet’s Disease Cohort Identifies Genetic Associations in a Long Noncoding RNA Near QSOX2, RASIP1/FUT2, and IL12A-AS1

    Paul Renauer1, Patrick Coit1, Travis Hughes2, Mikhail Ognenovski1, Adam Adler3, Lourdes Ortiz-Fernández4, Vuslat Yilmaz5, Kenan Aksu6, Nursen Duzgun7, Gokhan Keser8, Ayse Cefle9, Ayten Yazici10, Andac Ergen11, Erkan Alpsoy12, Carlo Salvarani13, Bruno Casali14, Ina Koetter15, Alexandra Zhernakova16, Cisca Wijmenga17, Fujio Takeuchi18, Shinji Harihara19, Toshikatsu Kaburaki20, Yeong Wook Song21, Francisco David Carmona22, Marta E. Alarcon Riquelme23, Javier Martín22, Güher Saruhan-Direskeneli24, María Francisca Gonzalez Escribano25, Haner Direskeneli26 and Amr H Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, 3Oklahoma Medical Research Foundation, OK, OK, 4Immunology department, Hospital Universitario Virgen del Rocío, Sevilla, Spain, 5Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, 6İnternal Medicine Division of Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 7Internal Medicines, Rheumatology Department, Ankara University School of Medicine, Ankara, Turkey, 8Rheumatology, Ege University Medical Faculty, Izmir, Turkey, 9Rheumatology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey, 10Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, 11Okmeydaný Research and Education Hospital, Istanbul, Turkey, 12Department of Dermatology, Akdeniz University School of Medicine, Antalya, Turkey, 13Rheumatology, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, 14Molecular Biology Laboratory, Azienda Ospedaliera Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy, 15Internal Medicine IV Rheumatology, Asklepios Klinik Altona, Hamburg, Germany, 16Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, 17Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, 18#504 Lab/ Dep of Internal Medicine (Allergy & Rheumatology), Faculty of Medicine, University of Toyko, Tokyo, Japan, 19Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, 20Ophthalmology, The University of Tokyo School of Medicine, Bunkyo-ku, Japan, 21Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea, 22Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, 23Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain, 24Department of Physiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 25Hospital Universitario Virgen del Rocío (IBiS,CSIC,US), Sevilla, Spain, 26Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose:  Behçet’s disease is a chronic relapsing inflammatory disease characterized by recurrent mucocutaneous involvement. We performed dense genotyping in immune related loci in a large…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology